|
|
 |
|
Gazette Highlights News 1998 |
Click on a week to view more
Week
51:
- Enzacta R&D was formed in 1998 by the merger of ProDrug Pharma
and Aepact, and now the first patent application in the new name
has appeared...
- No fewer than 12 simultaneous applications from Schering Corp
relate to novel inhibitors of farnesyl protein transferase accompanied
by two further publications...
- Purdue Pharma, the Connecticut-based associate of Mundipharma,
appears to be quite a normal pharmaceutical company, with a particular
interest in sustained release formulations...
- Soane BioSciences, now apparently called ACLARA BioSciences,
claims a microchannel device that may be used in high throughput
screening...
- Not exactly high-tech, but nevertheless well-timed for the seasonal
festivities, a publication from Otsuka describes how Salmonella
infection...
|
Week
50:
- Australian technology transfer broker Unisearch has teamed up
with The Garvan Institute of Medical Research, mentioned only
last week as a collaborative innovator...
- This week Chiron describes how tumor therapy regimes may be
planned on the basis of the mutational status of the huBUB1 gene...
- Nanosphere technology is the subject of two applications from
Johns Hopkins University...
- Development of amprenavir at the former Wellcome site in Dartford
has led to the patenting of a novel polymorph, described as Form
V in a new Glaxo publication...
- Abbott's UK site is the source of an application covering a
once-daily controlled release formulation of clarithromycin, based
on alginic acid complex salts...
|
Week
49:
- Two pairs of applications this week seem to originate from Dublin,
although in one instance it seems the work was carried out in
Italy. Comments were made in mid-1997 about indane dimer applications...
- It is clear that the Royal Free Hospital School of Medicine
in north London is collaborating with Neuroimmuno Therapeutics
Research of Spartanburg in South Carolina...
- At first there seems nothing to link the invention from Caliper
Technologies with pharmaceuticals, since it relates to microfluidic
devices...
- More University inventions than usual are among the applications
published this week, and most are in the biotech field...
- Merck continues to develop its portfolio of gonadotropin releasing
hormone antagonists with five new applications describing novel
indole compounds...
|
Week
48:
- Materials science and robotics are now drawing on biotech and
combinatorial techniques in the search for precision in the manufacture
of components. Boehringer Mannheim, employing Danish expertise...
- Senju, primarily specialising in ophthalmological preparations,
has a strong background of collaborative projects, and is now
seen to be involved with Yoshitomi in the development of israpafant...
- Akzo has the latest of many cases describing mianserin-type
tetracyclic 5-HT antagonists, but on this occasion the claims
are simply to a novel salt, the besylate...
- SB's penicillin plant at Irvine, in Scotland, employs fermentation
technology from Gist-Brocades, supplied under the terms of a collaborative
agreement...
|
Week
47:
- Fourteen Japanese inventors have pooled their skills to produce
a patent application claiming bisaryl anticancer agents. The joint
applicants are Kyowa Hakko Kogyo and Fuji Photo Film...
- The UK Medical Research Council has six applications published
this week, four covering nucleic acid binding proteins of the
Cys2-His2 zinc finger class...
- Innovation by Schering-Plough only rarely has its origins in
Italy. However, there are now indications of development work
being carried out there on adenosine A2 antagonists...
- Helpfully, Glaxo names 1592U89 (abacavir) in the titles of two
applications, rather than leave the reader to work out precisely
which antiviral is preferred...
- Lynx Therapeutics of California, with three antisense nucleosides
already in clinical trials for neoplasm and leukemia, has enlisted
the help of Sydney Brenner...
- For a decade now, a group of Croatians have been patenting therapeutic
peptides known as Body Protection Compounds, or BPC...
|
Week
46:
- Merck's transgenic research now extends to presenilin, a field
already under investigation by companies such as SmithKline Beecham
and Bayer...
- Pfizer, whose Zithromax (azithromycin) was licensed from Pliva,
continues to study erythromycins with novel substitution patterns,
whilst Abbott, another company...
- Bayer and Sumitomo, already in a joint venture unrelated to
pharmaceuticals, may also now be collaborating on bridged anthracene
derivatives...
- An unusual non-drug therapy relates to a method of treating
stroke using CPAP, is continuous positive airway pressure, or
nasal ventilation, under the control of physiological feedback...
|
Week
45:
- GABA receptor ligands are now the target for two separate teams
at Merck Sharp & Dohme's UK site, as emphasised by the simultaneous
publication of two applications...
- Canada, perhaps unexpectedly, is the source of an application
from Astra relating to peptidomimetic opioid analgesics...
- Fusion proteins are used by PPL Therapeutics to produce amidated
peptides, and this application serves as a reminder of the pioneering
work on transgenics...
- The TGF-alpha protein superfamily, and more particularly bone
morphogenic protein, is under investigation independently by two
Massachusetts-based companies targeting kidney disease...
|
Week
44:
- Not content with the undeniable success achieved already by
Viagra, Pfizer continues to synthesise novel PDE-V inhibitors,
retaining the same pyrazolopyrimidinone template...
- Lilly's protection for raloxifene and its analogues, already
vast in its scope, is further reinforced by a series of applications
relating to chemical processes and intermediates...
- On opposite shores of the North Sea, Novo Nordisk and the University
of Newcastle are collaborating on the genome of B subtilis...
|
Week
43:
- Metalloproteinase gene research at BMS is being undertaken in
collaboration with French institutes, including Louis Pasteur,
INSERM and CNRS...
- The MTP inhibitors claimed originally in WO9640640 are now the
subject of process patenting by Pfizer, indicating that a lead...
- A switch of development partner seems to be implied by a case
in which Abbott claims the synthesis of ACEA-1021, the NMDA antagonist...
- An unfortunate printer's error has resulted in details of Banyu's
new neuropeptide Y antagonist being concealed from the public
for a further week...
|
Week
42:
- Enantiomer manufacture patenting this week offers a strong pointer
to a previously unreported development candidate. It is now some
time since Astra...
- Natural products are prominent in this week¿s patenting, which
includes a case from the Spanish marine organism specialist Pharma
Mar. The antimicrobials claimed...
- Three inventions from Genzyme, naming a total of eight inventors,
relate to adenoviral vectors, the object being to achieve increased
persistence of transgene expression...
- Lilly yet again has a string of new use inventions, some relating
to cryptophycin, and others to a methoxyimino acetonitrile muscarinic
agonist...
|
Week
41:
- US biotech research is focused on California and Massachusetts,
and two patent applications published this week serve to highlight
the competitive nature of the discovery activity...
- Process chemistry might be seen as the poor relation of drug
discovery, at least in patent terms, but a case published this
week seems to go some way to correcting that image. In a Pfizer...
- Lilly¿s sequence of new use patenting continues with applications
relating to cryptophycin andfor diarylsulfonylureas such as sulofenur...
- This week also sees a rare biotech application from NASA in
conjunction with Tulane University...
|
Week
40:
- Biotech collaborations, especially from France and the US, are
prominent in this week's patenting. HGS is a partner in three
of these, collaborating with Long Island Jewish Medical Center...
- Two expatriats, one British and the other Irish, appear as inventors
on an application from the Massachusetts-based company Genzyme,
filed jointly with a less well-known company, PolyMASC...
- Cuba has a particularly well developed biotech discovery capability,
and a dozen or so sophisticated inventions from Cuban institutions...
- Companies new to patenting or with little previous activity
include Inkine, claiming purgative formulations, and Simeg...
|
Week
39:
- Serotonin modulators continue to attract the attention of researchers
in France. Pierre Fabre?piperazines antagonise a range of subtypes
of the 5-HT1 receptor...
- The Australian company Luminis, previously specialising in antibacterials
and antivirals, including frog skin peptides, is now turning attention
to 5-HT2C modulators...
- Vigorous patenting of leukotriene modulators by Lilly over the
past decade has yielded several promising antiinflammatories and
antiasthmatics...
|
Week
38:
- Clusters of cases appearing this week include eight from Incyte
on the subject of various human receptor proteins, and eleven
from Astra describing inhalation devices...
- To see a joint application from the UK¿s Medical Research Council
and the University of Glasgow is not too unexpected, given the
role played by MRC in assisting academic institutions...
- The small amount of international patenting to have emerged
so far from Cubist Pharmaceuticals of Massachusetts has been concerned
with antibacterial mechanisms...
- Among seven SB applications appearing this week are two relating
to calpain inhibitors, one filed jointly with Cephalon Inc; this
collaborative programme...
|
Week
37:
- Over the past decade Chiroscience has intensively researched
the resolution of known therapeutic agents, and has frequently
identified therapeutic advantages associated with...
- Beacon Laboratories of New Jersey, a name first seen on a patent
specification only two months ago, now has a series of six applications
claiming the use of oxyalkylene esters...
- Searle, whose leukotriene synthesis inhibitors SC-56938 and
SC-57461 are already under investigation as antiinflammatories,
is focusing on LTA 4 hydrolase inhibitors...
- Polypeptide components of the human circadian clock are claimed
by workers at Northwestern University. This work is linked, through
one of the inventors...
|
Week
35:
- Atropisomerism has been identified by Pfizer in a series of
quinazoline derivatives...
- Analytical technology gives rise to several unusual cases, including
one concerned with nucleic acid analysis from Exact Laboratories...
- Clavaspirins are described this week by an inventor at the University
of California...
- Bearsden Bio had a publication last week relating to identification
of RNA binding sites, and now has claims to computer models for
protein-ligand interactions...
|
|
Back to top
|
|
|
|
|
